Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

被引：0
|
作者：
Gross-Goupil, M. [1 ]
Kwon, T. G. [2 ]
Eto, M. [3 ]
Ye, D. [4 ]
Miyake, H. [5 ]
Seo, S. I. [6 ]
Byun, S. S. [7 ]
Lee, J. L. [8 ]
Master, V. [9 ]
Jin, J. [10 ]
Debenedetto, R. [11 ]
Linke, R. [12 ]
Casey, M. [13 ]
Rosbrook, B. [14 ]
Frean, M. J. Lechuga [15 ]
Valota, O. [16 ]
Grande, E. [17 ]
Quinn, D. I. [18 ]
机构：
[1] Hop St Andre, Dept Oncol, CHU Bordeaux, Bordeaux, France
[2] Kyungpook Natl Univ, Sch Med, Daegu, South Korea
[3] Kyushu Univ, Dept Clin Med, Fukuoka, Fukuoka, Japan
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Hamamatsu Univ, Sch Med, Hamamatsu, Shizuoka, Japan
[6] Sungkyunkwan Univ, Dept Urol, Seoul, South Korea
[7] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[8] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[9] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
[10] Peking Univ, Dept Urol, Hosp 1, Beijing, Peoples R China
[11] SFJ Pharmaceut, Clin Dev & Med Affairs, Pleasanton, CA USA
[12] SFJ Pharmaceut Inc, Clin Dev & Med Affairs, Pleasanton, CA USA
[13] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[14] Pfizer Inc, Translat Oncol, La Jolla, CA USA
[15] Pfizer Italia Srl, Dept Oncol, Milan, Italy
[16] Pfizer Srl, Dept Oncol, Milan, Italy
[17] MD Anderson Canc Ctr Ctr Espana, Dept Med Oncol, Madrid, Spain
[18] Univ Southern Calif, Translat & Clin Sci Program, Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
863O
引用
收藏
页码：303 / 303
页数：1
相关论文
共 50 条
  • [1] ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
    Kwon, Tae Gyun
    Seong, Seo
    Byun, Seok-Soo
    Miyake, Hideaki
    Ueda, Takeshi
    Ye, Dingwei
    Garcia-Donas, Jesus
    Gross-Goupll, Marine
    Hutson, Thomas E.
    DeBenedetto, Robert
    Hariharan, Subramanian
    Lee, Min Young
    Linke, Rolf Gerhard
    Tsuji, Fumito
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
    Gross-Goupil, M.
    Kwon, T. G.
    Eto, M.
    Ye, D.
    Miyake, H.
    Seo, S. I.
    Byun, S-S
    Lee, J. L.
    Master, V.
    Jin, J.
    DeBenedetto, R.
    Linke, R.
    Casey, M.
    Rosbrook, B.
    Lechuga, M.
    Valota, O.
    Grande, E.
    Quinn, D. I.
    ANNALS OF ONCOLOGY, 2018, 29 (12) : 2371 - 2378
  • [3] Re: Axitinib versus Placebo as an Adjuvant Treatment of Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial
    Laguna, M. Pilar
    JOURNAL OF UROLOGY, 2019, 202 (01): : 27 - 28
  • [4] Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.
    Quinn, David I.
    Kwon, Tae Gyun
    Eto, Masatoshi
    Ye, Dingwei
    Miyake, Hideaki
    Seo, Seong Il
    Byun, Seok-Soo
    Lee, Jae-Lyun
    Master, Viraj A.
    Ng, Chi-Fai
    Linke, Rolf Gerhard
    Rosbrook, Brad
    Thakur, Mahgull Nazar
    Grande, Enrique
    Gross-Goupil, Marine
    Chang, Chao-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] PHASE 2 RANDOMIZED DISCONTINUATION TRIAL (RDT) OF TIVOZANIB IN PATIENTS WITH RENAL CELL CARCINOMA (RCC): RESULTS IN PATIENTS RANDOMIZED TO TIVOZANIB VS. PLACEBO
    Nosov, D. A.
    Bhargava, P.
    Esteves, B.
    Al-Adhami, M.
    Lipatov, O.
    Lyulko, A. A.
    Anischenko, A. A.
    Chacko, R.
    Doval, D. C.
    Slichenmyer, W.
    ANNALS OF ONCOLOGY, 2010, 21 : 271 - 271
  • [6] ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
    Quinn, D., I
    Ng, C. F.
    Grande, E.
    Kwon, T. G.
    Linke, R.
    Lee, J-L
    Rosbrook, B.
    Thakur, M. N.
    Eto, M.
    Gross-Goupil, M.
    ESMO OPEN, 2021, 6 (03)
  • [7] DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.
    Voss, Martin Henner
    Plimack, Elizabeth R.
    Rini, Brian I.
    Atkins, Michael B.
    Alter, Robert
    Bhatt, Rupal Satish
    Beck, J. Thaddeus
    Pappas, Kristen M.
    Wilson, Dawn
    Zhang, Xiaosha
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
    Ng, C. F.
    Kwon, T. G.
    Eto, M.
    Miyake, H.
    Seo, S. I.
    Byun, S-S.
    Lee, J. L.
    Rosbrook, B.
    Grande, E.
    Gross-Goupil, M.
    Quinn, D. I.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 1 dose escalation cohorts
    Voss, M. H.
    Plimack, E.
    Rini, B.
    Atkins, M. B.
    Alter, R.
    Beck, J. T.
    Bhatt, R. S.
    Pappas, K.
    Wilson, D.
    Sherman, M. L.
    Pandya, S.
    BJU INTERNATIONAL, 2014, 114 : 16 - 17
  • [10] Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H. S.
    Staehler, M.
    George, D.
    Pantuck, A. J.
    Patel, A.
    Chang, Y-H.
    Escudier, B.
    Donskov, F.
    Magheli, A.
    Carteni, G.
    Laguerre, B.
    Tomczak, P.
    Breza, J.
    Gerletti, P.
    Lin, X.
    Lechuga, M.
    Martini, J-F.
    Patard, J-J.
    ANNALS OF ONCOLOGY, 2016, 27
12345